Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential.

UNLABELLED An ideal hypoxia imaging agent should have high membrane permeability for easy access to intracellular mitochondria and low redox potential to confer stability in normal tissue, but it should be able to be reduced by mitochondria with abnormally high electron concentrations in hypoxic cells. In this context, nitroimidazole residues are not considered to be essential. In this study, Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM), a 62Cu-bisthiosemicarbazone complex, with high membrane permeability and low redox potential, was evaluated as a possible hypoxia imaging agent, using electron spin resonance spectrometry and the Langendorff isolated perfused rat heart model as well as rat heart left anterior descending occlusion model. METHODS Nonradioactive Cu-ATSM was incubated with rat mitochondria, after which reduction of Cu(II) to Cu(I) was measured with electron spin resonance. As a model of hypoxic mitochondria, rotenone (Complex I inhibitor)-treated mitochondria were used. RESULTS In this study, Cu-ATSM was reduced by hypoxic but not by normal mitochondria. CONCLUSION Thus, retention of 62Cu-ATSM was studied serially in perfused rat hearts under conditions of normoxia (95% O2 + 5% CO2), hypoxia (95% N2 + 5% CO2) and reoxygenation (95% O2 + 5% CO2). In normoxia and reoxygenation, 62Cu-ATSM injected as a single bolus showed low retention (23.77% and 22.80%, respectively) 15 min after injection, but retention was increased markedly under hypoxic conditions (81.10%). Also, in the in vivo left anterior descending occluded rat heart model, 62Cu-ATSM retention was inversely correlated with accumulation of 201Tl, a relative myocardial blood flow marker.

[1]  J. D. Chapman,et al.  Radioiodinated 1-(2-fluoro-4-iodo-2,4-dideoxy-beta-L-xylopyranosyl)-2-nitroimidazole: a novel probe for the noninvasive assessment of tumor hypoxia. , 1992, Radiation research.

[2]  L. Golberg,et al.  Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study. , 1992, British Journal of Cancer.

[3]  C. Ng,et al.  Kinetic analysis of technetium-99m-labeled nitroimidazole (BMS-181321) as a tracer of myocardial hypoxia. , 1995, Circulation.

[4]  B Chance,et al.  Evaluation of Cardiac Ischemia by NADH Fluorescence Photography , 1977, Annals of surgery.

[5]  C. Dence,et al.  Myocardial kinetics of fluorine-18 misonidazole: a marker of hypoxic myocardium. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  A. Nunn,et al.  TcO(PnA.O-1-(2-nitroimidazole)) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: synthesis, characterization, and xanthine oxidase-catalyzed reduction. , 1994, Journal of medicinal chemistry.

[7]  P. Pedersen,et al.  Proton ATPase of rat liver mitochondria: a rapid procedure for purification of a stable, reconstitutively active F1 preparation using a modified chloroform method. , 1984, Analytical biochemistry.

[8]  Y. Yonekura,et al.  Application of the new zinc-62/copper-62 generator: an effective labeling method for 62Cu-PTSM. , 1992, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[9]  K. Sakai,et al.  A device for recording left ventricular contraction and electrocardiogram in nonworking isolated perfused rat heart. , 1978, Japanese journal of pharmacology.

[10]  M. Green,et al.  Structure-activity relationships for metal-labeled blood flow tracers: comparison of keto aldehyde bis(thiosemicarbazonato)copper(II) derivatives. , 1990, Journal of medicinal chemistry.

[11]  A. Nunn,et al.  Synthesis, characterization, and in vitro evaluation of nitroimidazole--BATO complexes: new technetium compounds designed for imaging hypoxic tissue. , 1993, Bioconjugate chemistry.

[12]  S. Ochoa [123] Malic dehydrogenase from pig heart: l-Malate + DPN + ⇆ Oxalacetate + DPNH + H+ , 1955 .

[13]  F. Ota,et al.  Anisotropic inhibition of energy transduction in oxidative phosphorylation in rat liver mitochondria by tetraphenylarsonium. , 1980, The Journal of biological chemistry.

[14]  P. Workman,et al.  The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive metabolism and semiquantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis. , 1995, British Journal of Cancer.

[15]  C. H. Bayley,et al.  THE PREPARATION OF SOME THIOSEMICARBAZONES AND THEIR COPPER COMPLEXES: PART III , 1960 .

[16]  M J Welch,et al.  Synthesis and biodistribution of 18F-labeled fluoronitroimidazoles: potential in vivo markers of hypoxic tissue. , 1986, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[17]  R. Pennington Biochemistry of dystrophic muscle. Mitochondrial succinate-tetrazolium reductase and adenosine triphosphatase. , 1961, The Biochemical journal.

[18]  Y. Fujibayashi,et al.  Effects of ischemia-reperfusion injury on myocardial single pass extraction and retention of Cu-PTSM in perfused rat hearts: comparison with 201T1 and 14C-iodoantipyrine. , 1994, Nuclear medicine and biology.

[19]  J. Brown,et al.  Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. , 1980, Radiation research.

[20]  D. Petering,et al.  Structure-function correlations in the reaction of bis(thiosemicarbazonato) copper(II) complexes with Ehrlich ascites tumor cells. , 1978, Cancer research.

[21]  John M. Hoffman,et al.  Binding of the hypoxia tracer [3H]misonidazole in cerebral ischemia. , 1987, Stroke.

[22]  G. Adams,et al.  Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. , 1976, Radiation research.

[23]  J. D. Chapman,et al.  Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. , 1983, Cancer research.

[24]  J. Downey,et al.  Xanthine oxidase: a critical mediator of myocardial injury during ischemia and reperfusion? , 1986, Acta physiologica Scandinavica. Supplementum.

[25]  H. Strauss,et al.  Comparison of technetium-99m-glucarate and thallium-201 for the identification of acute myocardial infarction in rats. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  W. Rumsey,et al.  Effect of graded hypoxia on retention of technetium-99m-nitroheterocycle in perfused rat heart. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  Y. Yonekura,et al.  Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) (Cu-PTSM), a metal complex with selective NADH-dependent reduction by complex I in brain mitochondria: a potential radiopharmaceutical for mitochondria-functional imaging with positron emission tomography (PET). , 1995, Biological & pharmaceutical bulletin.

[28]  A. Lott,et al.  Copper as a hypoxic cell sensitizer of mammalian cells. , 1978, The British journal of cancer. Supplement.

[29]  Y. Yonekura,et al.  A new zinc-62/copper-62 generator as a copper-62 source for PET radiopharmaceuticals. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.